2024年10月30日盘前,生物制药公司Arvinas(ARVN.US)股价大涨8.95%,一度触及29.06美元/股高位,成交量与前一交易日相比大幅增加。
公司此前公布了截至2024年9月30日的上一财季业绩数据。财报显示,Arvinas在该财季实现营收1.024亿美元,相比去年同期的3900万美元大幅增长196%,也超过了分析师平均预期的5742万美元。公司调整后每股亏损68美分,也好于市场预期的96美分。
业内人士指出,Arvinas财报数据优于预期,令投资者看好公司通过专有技术打造蛋白质降解疗法的前景。作为生物制药行业新兴公司,Arvinas在抗衰老药物研发领域具有一定潜力,今年以来也获得了多家机构的买入评级,可能是导致盘前大涨行情的原因之一。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.